N

NewGLab Pharma Co Ltd
KOSDAQ:214870

Watchlist Manager
NewGLab Pharma Co Ltd
KOSDAQ:214870
Watchlist
Price: 6 915 KRW -27.44% Market Closed
Market Cap: 323.6B KRW
Have any thoughts about
NewGLab Pharma Co Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one NewGLab Pharma Co Ltd stock under the Base Case scenario is 158.63 KRW. Compared to the current market price of 6 915 KRW, NewGLab Pharma Co Ltd is Overvalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
158.63 KRW
Overvaluation 98%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Valuation Multiples

53
P/S
P/S
Price to Sales
53
vs History
36
vs Industry
13
Median 3Y
18.3
Median 5Y
16
Industry
1.8
More Details
1 114.2
P/E
P/E
Price to Earnings
1 114.2
vs History
0
vs Industry
59
Median 3Y
-4.7
Median 5Y
-9.4
Industry
23.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
31
Median 3Y
-24.2
Median 5Y
-19.8
Industry
14.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-16.7
Median 5Y
-16.7
Industry
20
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-11.2
Median 5Y
8
Industry
2
More Details
52.5
EV/S
EV/S
Enterprise Value to Sales
52.5
vs History
34
vs Industry
13
Median 3Y
17.1
Median 5Y
15.3
Industry
1.8
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
1
Median 3Y
120.3
Median 5Y
93.2
Industry
7.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-20.6
Median 5Y
-25.1
Industry
14.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-16.9
Median 5Y
-21.4
Industry
18.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
31
Median 3Y
-23.9
Median 5Y
-18.9
Industry
14.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
25
Median 3Y
-22.5
Median 5Y
-19.2
Industry
17.9
More Details
27.7
EV/IC
EV/IC
Enterprise Value to IC
27.7
vs History
49
vs Industry
9
Median 3Y
12.7
Median 5Y
7.2
Industry
1.6
More Details

Multiples Across Competitors

Competitors Multiples
NewGLab Pharma Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
NewGLab Pharma Co Ltd
KOSDAQ:214870
323.6B KRW 53 1 114.2 -29.5 -27.1
JP
Keyence Corp
TSE:6861
15.6T JPY 15.3 40.9 26.8 27.5
CN
Hangzhou Hikvision Digital Technology Co Ltd
SZSE:002415
288.1B CNY 3.1 21.6 17.3 17.3
US
Keysight Technologies Inc
NYSE:KEYS
28.2B USD 5.7 45.9 25.5 33.8
SE
Hexagon AB
STO:HEXA B
283.3B SEK 4.6 24.5 14.8 19
US
Teledyne Technologies Inc
NYSE:TDY
21.9B USD 3.9 23.2 18 23.4
US
Zebra Technologies Corp
NASDAQ:ZBRA
20.3B USD 4.4 53 27 34.4
US
Trimble Inc
NASDAQ:TRMB
17.5B USD 4.8 11.8 29.5 42.7
IL
Mobileye Global Inc
NASDAQ:MBLY
14.2B USD 7.9 -4.8 95.6 -34.8
UK
Halma PLC
LSE:HLMA
10.3B GBP 5.1 38.2 22.7 29.1
JP
Shimadzu Corp
TSE:7701
1.3T JPY 2.5 25.2 12.9 16.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
N
NewGLab Pharma Co Ltd
KOSDAQ:214870
Average EV/EBIT: 27.1
Negative Multiple: -27.1 		N/A N/A
JP
Keyence Corp
TSE:6861
27.5
N/A N/A
CN
Hangzhou Hikvision Digital Technology Co Ltd
SZSE:002415
17.3
43%
0.4
US
Keysight Technologies Inc
NYSE:KEYS
33.8
112%
0.3
SE
Hexagon AB
STO:HEXA B
19
15%
1.3
US
Teledyne Technologies Inc
NYSE:TDY
23.4
30%
0.8
US
Zebra Technologies Corp
NASDAQ:ZBRA
34.4
102%
0.3
US
Trimble Inc
NASDAQ:TRMB
42.7
113%
0.4
IL
M
Mobileye Global Inc
NASDAQ:MBLY
Negative Multiple: -34.8 N/A N/A
UK
Halma PLC
LSE:HLMA
29.1
45%
0.7
JP
Shimadzu Corp
TSE:7701
16.4
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.